Immunohistochemistry in gynaecological pathology: a review

Marjoniemi, Veli

doi:10.1080/00313020410001671948

Cited by 29 publications

(18 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings regarding RARα expression confirm previous reports [10,20] and additionally show that in ovarian cancer, RARβ is not downregulated as RARα increases, as reported previously in oral cancer [7]. …”

Section: Discussionsupporting

confidence: 82%

“…Recently, the expression of all classes of retinoid receptors (RARs and RXRs) in ovarian cancer was reported for the first time and only RARα was an independent negative prognostic factor of survival [20]. In our study, RARα low expression was associated with a better response to the first-line chemotherapy (TC) and prolonged progress-free survival (PFS), and multivariate analysis suggested it as an independent prognostic factor.…”

Section: Discussionmentioning

confidence: 53%

“…Immunohistochemistry was shown to be valuable in evaluating prognostic factors in serous ovarian carcinoma [19,20]. Our study focused on RARα, RARβ, and ERα.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Retinoid Receptor Alpha and Beta Expression in Serous Ovarian Tumors

Daponte

Kostopoulou²,

Chiotoglou³

et al. 2007

Oncology

View full text Add to dashboard Cite

The expression of retinoid acid receptors α (RARα) and β (RARβ) and estrogen receptor α (ERα) was assessed by immunohistochemistry and Western blotting in normal ovaries, serous cystadenoma (n = 20), serous borderline (n = 14), and serous ovarian cancer (n = 47) and was correlated in cancer cases with stage, grade, progress-free survival (PFS), and survival. RARα was increasingly expressed in benign cystadenomas, borderline, and low-stage and advanced-stage neoplasms (p < 0.001). In stage III, G3 serous carcinoma, increased RARα expression was an independent prognostic factor associated with lower chemoresponse to first-line chemotherapy (taxol and carboplatin) and shorter PFS (p < 0.002).RARβ and ERα expression did not correlate with RARα tumor characteristics or PFS and survival.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 53%

See 1 more Smart Citation

Retinoid Receptor Alpha and Beta Expression in Serous Ovarian Tumors

Daponte

Kostopoulou²,

Chiotoglou³

et al. 2007

Oncology

View full text Add to dashboard Cite

show abstract

“…Additionally, we reported that the years of practice and time spent on gyn service significantly affected IHC use among pathologists, with less use for practitioners with more than 10 years of practice and more than 10 weeks/year of service. The specific aims of the current part 2 report were (1) to compare the use of IHC in diagnostic gyn pathology between 2 academic tertiary care centers, namely, VU and Ohio State University (OSU); (2) to identify what IHC stains are preferentially used in diagnostic gyn pathology; and (3) to document the value of the most commonly used IHC markers in diagnostic gyn pathology. Toward these aims, we retrospectively reviewed the IHC biomarkers used in diagnostic gyn pathology at the two academic centers, which are located at two different geographic locations.…”

Section: Introductionmentioning

confidence: 99%

“…However, sometimes distinguishing benign from malignant process and knowing the cell of origin especially in poorly differentiated tumors are a challenge. Immunohistochemistry (IHC) has become an integral part in diagnostic pathology as an adjunct technique helping in resolving diagnostic dilemmas and used as predictive and prognostic markers beside others [1][2][3][4][5][6][7]. The use of IHC is widely varied in different practices and even among different pathologists in the same practice [8].…”

Section: Introductionmentioning

confidence: 99%